Aquestive Therapeutics (AQST) Announces Expert Allergy Scientific Advisory Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- McKesson reports cybersecurity incident affecting its information systems
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
Aquestive Therapeutics Announces Expert Allergy Scientific Advisory Board
September 12, 2022 4:01 PM EDTWARREN, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today the establishment of a Scientific Advisory Board comprised of eight allergy experts.
We are very pleased to welcome these leading experts to our Scientific Advisory Board, said Dan Barber, Chief Executive Officer of Aquestive. The accomplished individuals on our board have made significant contributions and breakthroughs in the Allergy and Immunology... More
